SearchDictionaryMobileLogin

thiopurine methyltransferase (thiopurine S-methyltransferase)

Subscribe to Selected New Research on thiopurine methyltransferase
144  relevant articles (6 outcomes, 13 trials/studies) found for this Bio-Agent
Also Known As:
thiopurine S-methyltransferase; S-adenosyl-L-methionine thiopurine S-methyltransferase

Relationship Network

Bio-Agent Context: Research Results

-
Enzymes and Coenzymes: 1
-
Enzymes: 25587
-
Transferases: 3318
-
One-Carbon Group Transferases
-
Methyltransferases: 202
*
thiopurine methyltransferase: 144

Experts

1. Gisbert, Javier P: 5 articles (12/2006 - 06/2003)
2. Cara, Carlos: 4 articles (12/2006 - 06/2003)
3. Schwab, Matthias: 3 articles (02/2007 - 08/2002)
4. Maté, José: 3 articles (11/2006 - 06/2003)
5. Pajares, José María: 3 articles (09/2005 - 06/2003)
6. Gaffney, D: 2 articles (05/2007 - 09/2004)
7. Shapiro, D: 2 articles (05/2007 - 09/2004)
8. Spooner, R J: 2 articles (05/2007 - 09/2004)
9. Mills, P R: 2 articles (05/2007 - 09/2004)
10. Herfarth, Hans: 2 articles (02/2007 - 12/2005)

Related Diseases

1. Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
2. Crohn Disease (Crohn's Disease)
3. Drug Toxicity (Drug Safety)
4. Leukemia
5. Neutropenia
01/01/2006 - "The effects of genotyping or phenotyping a population for thiopurine methyltransferase (TPMT) status were compared using the prevalence of TPMT deficiency in Caucasians, the relative risks of neutropenia and the associated costs. "
09/23/1995 - "We report a case of severe neutropenia after kidney transplantation due to a thiopurine methyltransferase deficiency. "
03/01/2002 - "The thiopurine methyltransferase activity was significantly lower in patients who discontinued azathioprine due to neutropenia than in those who discontinued due to other side-effects."
10/01/2008 - "The study confirmed the association of thiopurine methyltransferase heterozygosity with leucopenia and neutropenia in ALL patients and reported a significant association between inosine triphosphatase IVS2+21A-->C variants with thrombocytopenia (P = 0.012). "
08/01/1997 - "We have learned, for example, the following: high-dose methotrexate is more effective than lower-dose methotrexate, especially for T-cell ALL; patients who need drastic adjustment of mercaptopurine dosage due to thiopurine S-methyltransferase deficiency can be prospectively identified; dexrazoxane (ICRF-187) could reduce anthracycline cardiotoxicity; granulocyte colony-stimulating factor can shorten hospital stays for febrile neutropenia after intensive remission induction therapy; and prolonged low-dose epipodophyllotoxin treatment may reduce the risk of therapy-induced acute myeloid leukemia without compromising treatment efficacy. "
Order ALL the reference details at left...

Related Drugs and Biologics

1. Azathioprine (Imuran)
2. 6-Mercaptopurine (Mercaptopurine)
3. Inosine Triphosphate (ITP)
4. Transferases
5. Hypoxanthine
6. Granulocyte Colony-Stimulating Factor (G-CSF)
7. Sodium
8. Razoxane (Dexrazoxane)
9. Podophyllotoxin (Condylox)
10. Methotrexate (Mexate)

Related Therapies and Procedures

1. Remission Induction
2. Transplantation (Transplant Recipients)
3. Drug Therapy (Chemotherapy)
4. Organ Transplantation
5. Kidney Transplantation

Best Treatments:
Research Summary Report
on Inflammatory Bowel Diseases

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.
  • Free Updates for 1 Year
  • All 395 Outcomes
  • Top 200 Key Drugs and Biologics
  • Top 50 Key Therapies and Procedures
  • Detailed History Charts
  • Full Research Reference Details
  • Sample PDF Report on Psoriasis >>
Price:$24.00 & Delivery via PDF download
updates for 1 year
Research Interface

 

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.
  • Unlimited Disease, Drug and Therapy Search
  • 2 clicks from Disease to Drug to Evidence
  • Trial References
  • All the Positive Outcomes
  • Detailed Relationship Timeline Charts
  • Full Article Reference Details
  • Includes Mobile Interface Subscription
  • One-click to FDA Products/Patents
  • Request Institution License Details >>
Price:$490.00 access via web interface
1 year subscription
Proceed to Checkout >>
Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.
  • Access from any web enabled PDA or Phone
  • Trial references
  • All the Positive Outcomes
  • Drug and Therapy searches
  • Full Article Reference Details
  • Try Mobile Interface >>
Price:$45.00 access via "curehunter.com/m"
1 year subscription
Proceed to Checkout >>